Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LETROZOLE

All products: general benefit

Other products in the same Health Canada class (L02B, L02BG) — coverage varies; not interchangeable

  • Anastrozole (Arimidex): general benefit
  • Exemestane (Aromasin): general benefit
  • Abiraterone (Zytiga): general benefit
  • Bicalutamide (Casodex): general benefit, Not a benefit
  • Degarelix (Firmagon): general benefit
  • Flutamide (Euflex): general benefit, Not a benefit

3 more in the class list below

Femara · DIN 02231384 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Femara · DIN 02231384 Manufacturer: Novartis Pharma Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 1997-09-02 · brand FEMARA · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.3780 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50695 · Verify on the e-Formulary ↗ (DIN 02231384)

Source record
DIN 02231384: Femara Raw flags: sec3=Y Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id NOV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $8.9293; ministry $1.3780 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231384 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50695
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780 CCP-Letrozole · DIN 02459884 · $1.3780 Jamp Letrozole Tablets · DIN 02541912 · $1.3780 Jamp-Letrozole · DIN 02373009 · $1.3780 Letrozole · DIN 02348969 · $1.3780 Letrozole · DIN 02504472 · $1.3780 Letrozole · DIN 02524244 · $1.3780 Letrozole Tablets USP · DIN 02338459 · $1.3780 Mar-Letrozole · DIN 02373424 · $1.3780 Med-Letrozole · DIN 02322315 · $1.3780 Mint-Letrozole · DIN 02508109 · $1.3780 NRA-Letrozole · DIN 02520486 · $1.3780 Nat-Letrozole · DIN 02421585 · $1.3780 PMS-Letrozole · DIN 02309114 · $1.3780 Ran-Letrozole · DIN 02372282 · $1.3780 Riva-Letrozole · DIN 02398656 · $1.3780 Sandoz Letrozole · DIN 02344815 · $1.3780 Teva-Letrozole · DIN 02343657 · $1.3780 Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FEMARA® (letrozole) film-coated tablets is indicated for: • The adjuvant treatment of postmenopausal women with hormone receptor-positive invasive early breast cancer. Clinical effectiveness is based on superior Disease-Free Survival (DFS) compared to tamoxifen. Overall survival was not significantly different between the two treatments (see 14 CLINICAL TRIALS). • The extended adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy. Clinical effectiveness is based on superior Disease-Free Survival (DFS) compared to placebo in the overall study population, at a median follow-up of 28 months. However, overall survival was not significantly different between the two treatments for the overall population and an increase in deaths was seen in node-negative patients in the FEMARA arm versus the placebo arm (see 7 WARNINGS AND PRECAUTIONS and 14 CLINICAL TRIALS). • First-line therapy in postmenopausal women with advanced breast cancer. • … https://pdf.hres.ca/dpd_pm/00071188.PDF PM date: May 16, 1997 Source product: FEMARA; DIN 02231384; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.